CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $61.99, moving +1.66% from the previous trading session. This move outpaced the S&P 500's daily gain of 1.23%. Meanwhile, the Dow experienced a rise of 1.06%, and the technology-dominated Nasdaq saw an increase of 1.7%.
Prior to today's trading, shares of the company had gained 0.63% over the past month. This has lagged the Medical sector's gain of 3.16% and the S&P 500's gain of 0.94% in that time.
The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. It is anticipated that the company will report an EPS of -$0.22, marking an 84.4% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $144.28 million, showing a 1442670% escalation compared to the year-ago quarter.
It's also important for investors to be aware of any recent modifications to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 7.3% decrease. As of now, CRISPR Therapeutics AG holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 89, positioning it in the top 36% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
